Literature DB >> 18837244

Isolated extra-medullary relapse of acute leukemia following allogeneic bone marrow transplantation.

Al Sabty Firas1, E Demeckova, E Bojtarova, B Czako, M Hrubisko, M Mistrik.   

Abstract

Isolated extramedullary relapse (IEMR) of acute leukemia (AL) after allogeneic bone marrow transplantation (BMT) is a rare occurrence. It is seen more commonly after BMT than after conventional chemotherapy (CHT) alone. We describe the natural history and response to treatment in four patients with IEMR following allogeneic BMT. The results indicate a stronger graft-versus-leukemia (GVL) effect in the marrow than in the peripheral tissues (Fig. 4, Ref. 13). Full Text (Free, PDF) www.bmj.sk.

Entities:  

Mesh:

Year:  2008        PMID: 18837244

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  4 in total

1.  Isolated Breast Relapse of Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Esra Terzi Demirsoy; Elif Birtas Atesoglu; Pinar Tarkun; Ayfer Gedük; Büşra Erşan Erdem; Abdullah Hacihanefioglu; Mehmet Cengiz Erçin
Journal:  Indian J Hematol Blood Transfus       Date:  2015-06-05       Impact factor: 0.900

2.  Relapse of Acute Myeloid Leukemia with t(16;21)(p11;q22) Mimicking Autoimmune Pancreatitis after Second Allogeneic Bone Marrow Transplantation.

Authors:  Yuhei Kamada; Kazumi Suzukawa; Kenichi Taoka; Yasushi Okoshi; Yuichi Hasegawa; Shigeru Chiba
Journal:  ISRN Hematol       Date:  2011-01-10

3.  Granulocytic sarcoma of the breast in acute myeloid leukemia: Two case reports.

Authors:  Jianfei Fu; Jiansheng Luo
Journal:  Oncol Lett       Date:  2013-11-19       Impact factor: 2.967

Review 4.  Complete response of extramedullary relapse in breast of acute T lymphoblastic leukemia after bone marrow transplantation to chemoradiotherapy: a case report and literature review.

Authors:  Bailong Liu; Bin Liu; Xu Wang; Liang Guo; Xiaoliang Liu; Wei Han; Lihua Dong; Min Liu
Journal:  BMC Cancer       Date:  2016-11-09       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.